Testing dabogratinib for low-grade upper tract bladder cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a new targeted therapy pill, dabogratinib, for people with low-grade upper tract urothelial carcinoma (a type of cancer in the tubes that carry urine from kidneys to bladder). It may be an option if you have tumor tissue left after a biopsy and haven't had certain prior treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and willing to follow study procedures
- Your cancer must be confirmed as low-grade and low-risk in the upper urinary tract
- A tumor spot at least 5mm (about the size of a pencil eraser) must be left in place
- You must have past genetic testing results or be able to provide a tissue sample for genetic testing
- You must have good kidney, liver, and blood counts as determined by blood tests
- You cannot have had certain prior treatments, like BCG within the last year or chemotherapy in the bladder within 8 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, nadofaragene firadenovec, which uses a harmless virus to deliver a signal that helps your immune system fight low-grade cancer in the upper part of the urinary tract (the kidney area). It's given directly into the kidney through a small tube, and may avoid more invasive surgery.
This trial tests whether putting two chemotherapy drugs (gemcitabine and docetaxel) directly into the bladder can treat low-grade bladder cancer that is at intermediate risk. The goal is to see if this approach can help people avoid more invasive treatments.
This study tests an experimental pill called TYRA-300 for people with low-grade bladder cancer that hasn't spread into the muscle layer. The pill targets a specific gene change (FGFR3) found in the tumor. The goal is to see if it can slow or shrink the cancer.
This Phase 2 trial tests BL-B01D1 to treat people with advanced or metastatic urothelial (urinary tract) cancer and other solid tumors. You may be eligible if standard treatments are no longer working or are not available, and you can meet safety and cancer-measurement requirements.
This trial tests a new treatment called UGN-104 for people with low-grade upper tract urothelial cancer (a type of cancer in the tube that carries urine from the kidney to the bladder). The treatment is given directly into the kidney area to kill cancer cells without surgery.
This trial tests a new experimental drug combination (BL-B01D1 with a PD-1 immunotherapy) for advanced bladder cancer that has not yet been treated with whole-body therapy. The goal is to see if this combination can shrink tumors and help people live longer without their cancer getting worse.
Hear when a new Low Grade Upper Tract Urothelial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.